Диссертация (1140670), страница 24
Текст из файла (страница 24)
Brunner // Ann. Rheum. Dis. – 2015. – Vol. 74. –№ 6. – P. 1110–1117.14265.Burgos–Vargas, R. A 26 week randomised, double blind, placebo controlledexploratory study of sulfasalazine in juvenile onset spondyloarthropathies / R.Burgos–Vargas // Ann Rheum Dis. – 2002. – Vol. 61.
– № 10. – P. 941–942.66.Cassidy, J.T., Petty, R.E., Sullivan, D.B. Abnormalities in the distribution ofserum immunoglobulin concentrations in juvenile rheumatoid arthritis / J.T.Cassidy, R.E. Petty, D.B. Sullivan // J. Clin. Invest. – 1973. – Vol. 52. – № 8. –P. 1931–1936.67.Cleary, A.G. Intra–articular corticosteroid injections in juvenile idiopathicarthritis / A.G. Cleary // Arch. Dis.
Child. – 2003. – Vol. 88. – № 3. – P. 192–196.68.Consolaro, A. Advances in biomarkers for paediatric rheumatic diseases / A.Consolaro // Nat. Rev. Rheumatol. – 2014. – Vol. 11. – № 5. – P. 1–11.69.Consolaro, A. Clinical outcome measures in juvenile idiopathic arthritis / A.Consolaro // Pediatr. Rheumatol. Online J. – 2016. – Vol.
14. – № 1. – P. 23.70.Consolaro, A. Development and Validation of a Composite Disease ActivityScore for Juvenile Idiopathic Arthritis / A. Consolaro // Arthritis Rheum. –2009. – Vol. 61. – № 5. – P. 658–666.71.Cron, R.Q., Beukelman, T. Guilt by association – what is the true risk ofmalignancy in children treated with etanercept for JIA? / R.Q. Cron, T.Beukelman // Pediatr. Rheumatol.
Online J. – 2010. – Vol. 8. – № 1. – P. 23.72.Damasio, M.B. Synovial and inflammatory diseases in childhood: Role of newimaging modalities in the assessment of patients with juvenile idiopathicarthritis / M.B. Damasio // Pediatr. Radiol. – 2010. – Vol. 40. – № 6. – P. 985–998.73.Dekker, L. Safety of anti–TNFalpha therapy in children with juvenile idiopathicarthritis / L. Dekker // Clin.
Exp. Rheumatol. – 2004. – Vol. 22. – № 2. – P.252–258.74.Demirkaya, E. The distribution of juvenile idiopathic arthritis in the easternMediterranean: results from the registry of the Turkish Paediatric Rheumatology143Association / E. Demirkaya // Clin. Exp. Rheumatol. – 2016. – Vol.
29. – № 1.– P. 111–116.75.Diak, P. Tumor necrosis factor alpha blockers and malignancy in children:forty–eight cases reported to the Food and Drug Administration / P. Diak //Arthritis Rheum. – 2010. – Vol. 62. – № 8. – P. 2517–2524.76.Eichenfield, A.H. Utility of rheumatoid factor in the diagnosis of juvenilerheumatoid arthritis / A.H. Eichenfield // Pediatrics. – 1986. – Vol. 78. – № 3. –P. 480–484.77.Foeldvari, I., Becker, I., Horneff, G.
Uveitis Events During Adalimumab,Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: DataFrom the Biologics in Pediatric Rheumatology Registry / I. Foeldvari, I. Becker,G. Horneff // Arthritis Care Res (Hoboken). – 2015. – Vol. 67. – № 11.
– P.1529–1535.78.Foeldvari, I., Wierk, A. Effectiveness of leflunomide in patients with juvenileidiopathic arthritis in clinical practice / I. Foeldvari, A. Wierk // J. Rheumatol. –2010. – Vol. 37. – № 8. – P. 1763–1767.79.Geikowski, T. Predictors of response to etanercept in polyarticular–coursejuvenile idiopathic arthritis / T.
Geikowski [et al.] // Rheumatology (Oxford). –2014. – Vol. 53. – № 7. – P. 1245–1249.80.Gerloni, V. Efficacy and safety profile of cyclosporin A in the treatment ofjuvenile chronic (idiopathic) arthritis. Results of a 10–year prospective study /V. Gerloni [et al.] // Rheumatol. – 2001. – Vol. 40. – P. 907–913.81.Ghosh, J.B., Dipankar, G., Nibedita, C. Juvenile idiopathic arthritis withperipheral gangrene / J.B.
Ghosh, G. Dipankar, C. Nibedita // Indian J. Pediatr.– 2006. – Vol. 73. – № 8. – P. 739–741.82.Giancane, G., Consolaro, A. Juvenile Idiopathic Arthritis: Diagnosis andTreatment / J.B. Ghosh, G. Dipankar, C. Nibedita // Rheumatol Ther. – 2016. –Vol. 3. – № 2. – P. 187–207.83.Giannini, E.H. Long–term safety and effectiveness of etanercept in children144with selected categories of juvenile idiopathic arthritis / E.H. Giannini [et al.] //Arthritis Rheum. – 2009. – Vol.
60. – № 9. – P. 2794–2804.84.Giannini, E.H. Methotrexate in resistant juvenile rheumatoid arthritis – Resultsof the U.S.A.–U.S.S.R. double–blind, placebo–controlled trial / E.H. Giannini[et al.] // N. Engl. J. Med. – 1992. – Vol. 326. – № 16 PG–1043–1049. – P.1043–1049.85.Giannini, E.H. Prelimary definition of Improvement in Juvenile Arthritis / E.H.Giannini [et al.] // Arthritis and Rheumatol. – 1997. – Vol. 40.
– № 7. – P.1202–1209.86.Gibson, D.S. Stratification and monitoring of juvenile idiopathic arthritispatients by synovial proteome analysis / D.S. Gibson [et al.] // J. Proteome Res.– 2009. – Vol. 8. – № 12. – P. 5601–5609.87.Goldenberg, J. Symptomatic cardiac involvement in juvenile rheumatoidarthritis / J. Goldenberg [et al.] // Int. J. Cardiol.
– 1992. – Vol. 34. – № 1. – P.57–62.88.Gorelik, M. Follistatin–like protein 1 and the ferritin/erythrocyte sedimentationrate ratio are potential biomarkers for dysregulated gene expression andmacrophage activation syndrome in systemic juvenile idiopathic arthritis / M.Gorelik [et al.] // J. Rheumatol. – 2013. – Vol. 40. – № 7. – P. 1191–1199.89.Gowdie, P.J., Tse, S.M.L. Juvenile idiopathic arthritis / P.J. Gowdie, S.M.L. Tse// Pediatr.
Clin. North Am. – 2012. – Vol. 59. – № 2. – P. 301–327.90.Gutiérrez–Suárez, R. Health–related quality of life of patients with juvenileidiopathic arthritis coming from 3 different geographic areas. The PRINTOmultinational quality of life cohort study / R. Gutiérrez–Suárez [et al.] //Rheumatology (Oxford).
– 2007. – Vol. 46. № 2. – P. 314–320.91.Gutiérrez–Suárez, R., Burgos–Vargas, R. The use of methotrexate in childrenwith rheumatic diseases / R. Gutiérrez–Suárez, R. Burgos–Vargas // Clin. Exp.Rheumatol. – 2010. – Vol. 28. – № 5. – P. 61.92.Hahn, Y.–S., Kim, J.–G. Pathogenesis and clinical manifestations of juvenile145rheumatoid arthritis / Y.–S. Hahn, J.–G. Kim // Korean J.
Pediatr. – 2010. – Vol.53. – № 11. – P. 921–930.93.Harrold, L.R. Incidence and prevalence of juvenile idiopathic arthritis amongchildren in a managed care population, 1996–2009 / L.R. Harrold [et al.] // J.Rheumatol. – 2013. – Vol. 40. – № 7. – P. 1218–1225.94.Hashkes, P.J. Mortality outcomes in pediatric rheumatology in the US / P.J.Hashkes // Arthritis Rheum. – 2010. – Vol. 62. – № 2. – P. 599–608.95.Heiligenhaus, A.
Prevalence and complications of uveitis in juvenile idiopathicarthritis in a population–based nation–wide study in Germany: suggestedmodification of the current screening guidelines / A. Heiligenhaus //Rheumatology (Oxford). – 2007. – Vol. 46. – № 6. – P. 1015–1019.96.Heiligenhausб A. Review for disease of the year: epidemiology of juvenileidiopathic arthritis and its associated uveitis: the probable risk factors / A.Heiligenhaus [et al.] // Ocul. Immunol. Inflamm. – 2013.
– Vol. 21. – № 3. – P.180–191.97.Helmick, C.G. Estimates of the prevalence of arthritis and other rheumaticconditions in the United States. Part I / C.G. Helmick [et al.] // Arthritis Rheum.– 2008. – Vol. 58. – № 1. – P. 15–25.98.Hermann, G. Comorbidity of type 1 diabetes and juvenile idiopathic arthritis /G. Hermann // J. Pediatr. – 2015.
– Vol. 166. – № 4. – P. 930–935.99.Holzinger, D. The Toll–like receptor 4 agonist MRP8/14 protein complex is asensitive indicator for disease activity and predicts relapses in systemic–onsetjuvenile idiopathic arthritis / D. Holzinger [et al.] // Ann. Rheum. Dis. – 2012.
–Vol. 71. – № 6. – P. 974–980.100.Horneff, G. Safety and efficacy of combination of etanercept and methotrexatecompared to treatment with etanercept only in patients with juvenile idiopathicarthritis (JIA): preliminary data from the German JIA Registry / G. Horneff [etal.] // Ann. Rheum. Dis. – 2009. – Vol. 68. – № 4. – P.
519–525.101.Horneff, G. The German etanercept registry for treatment of juvenile idiopathic146arthritis / G. Horneff [et al.] // Ann. Rheum. Dis. – 2004. – Vol. 63. – № 12. – P.1638–1644.102.Horneff, G. Update on malignancies in children with juvenile idiopathic arthritisin the German BIKER Registry / G. Horneff [et al.] // Clin. Exp. Rheumatol. –2016. – Vol. 34(6). – P. 1113–1120.103.Hsin, Y.–C. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis:A Nationwide Population–Based Study in Taiwan / Y.–C. Hsin [et al.] // PLoSOne. – 2015.
– Vol. 10. – № 6. – P. e0128768.104.Huang, J.–L. New advances in juvenile idiopathic arthritis / J.–L. Huang //Chang Gung Med. J. – 2012. – Vol. 35. – № 1. – P. 1–14.105.Hunter, P.J. Biologic predictors of extension of oligoarticular juvenile idiopathicarthritis as determined from synovial fluid cellular composition and geneexpression / P.J. Hunter [et a.] // Arthritis Rheum. – 2010. – Vol. 62. – № 3. – P.896–907.106.Hurd, A., Beukelman, T.
Infectious complications in juvenile idiopathic arthritis/ A. Hurd, T. Beukelman // Curr. Rheumatol. Rep. – 2013. – Vol. 15. – № 5. –P. 327.107.Hyrich, K.L. Influence of past breast feeding on pattern and severity ofpresentation of juvenile idiopathic arthritis / K.L. Hyrich [et al.] // Arch. Dis.Child. – 2016. – Vol. 101. – № 4.
– P. 348–351.108.Jetha, A. Unpacking Early Work Experiences of Young Adults With RheumaticDisease: An Examination of Absenteeism, Job Disruptions, and ProductivityLoss / A. Jetha // Arthritis Care Res (Hoboken). – 2015. – Vol. 67. – № 9. – P.1246–1254.109.Kahn, P. Juvenile idiopathic arthritis – an update on pharmacotherapy / P. Kahn// Bull.
NYU Hosp. Jt. Dis. – 2011. – Vol. 69. – № 3. – P. 264–276.110.Kessler, E.A., Becker, M.L. Therapeutic advancements in juvenile idiopathicarthritis / E.A. Kessler, M.L. Becker // Best Pract. Res. Clin. Rheumatol. –2014. – Vol. 28. – № 2. – P. 293–313.147111.Kim, K.H., Kim, D.S. Juvenile idiopathic arthritis: Diagnosis and differentialdiagnosis / K.H. Kim, D.S. Kim // Korean J. Pediatr.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
